Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Valsartan recalled?

Yes — there is an active recall. 83 ongoing FDA recalls mention Valsartan (138 total). Check the affected lots below.

Recalls are matched by product description. A recall usually affects specific lots, not every package of Valsartan. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Valsartan recalls on record

none so far in 2026; 138 on record, newest first
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity A-S Medication Solutions LLC. NDC 54569-6582-0 D-1109-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity A-S Medication Solutions LLC. NDC 54569-6583-0 D-1108-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Teva Pharmaceuticals USA NDC 0591-2170-19 D-0989-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Teva Pharmaceuticals USA NDC 0591-2169-19 D-0988-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Teva Pharmaceuticals USA NDC 0591-2168-19 D-0987-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Teva Pharmaceuticals USA NDC 0591-2167-30 D-0986-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared excipient: Product batches were released into commercial distribution with a larger size grade of excipient (Crospovidone).

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-363-90 D-0876-2018
Class II · Moderate risk

Valsartan Tablets

Failed Tablet/Capsule Specifications: confirmed customer complaint of thicker and heavier tablets in bottle.

Terminated Failed specification Prinston Pharmaceutical Inc NDC 43547-369-09 D-0209-2018